Autologous peripheral blood progenitor cell mobilization and collection

Active Ingredient: Sargramostim

Indication for Sargramostim

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Sargramostim is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.

For this indication, competent medicine agencies globally authorize below treatments:

250 ug/m²/day administered intravenously over 24 hours

For:

Dosage regimens

Intravenous, 250 micrograms sargramostim per square meter of body surface, once daily.

Detailed description

The recommended dose is 250 mcg/m²/day administered intravenously over 24 hours. Continue at the same dose through the period of PBPC collection. The optimal schedule for PBPC collection has not been established. In clinical studies, collection of PBPC was usually begun after 5 days of sargramostim and performed daily until protocol specified targets were achieved.

If WBC greater than 50,000 cells/mm³, reduce the sargramostim dose by 50%. Consider other mobilization therapy if adequate numbers of progenitor cells are not collected.

250 ug/m²/day

For:

Dosage regimens

Subcutaneous, 250 micrograms sargramostim per square meter of body surface, once daily.

Detailed description

The recommended dose is 250 mcg/m²/day administered subcutaneously once daily. Continue at the same dose through the period of PBPC collection. The optimal schedule for PBPC collection has not been established. In clinical studies, collection of PBPC was usually begun after 5 days of sargramostim and performed daily until protocol specified targets were achieved.

If WBC greater than 50,000 cells/mm³, reduce the sargramostim dose by 50%. Consider other mobilization therapy if adequate numbers of progenitor cells are not collected.

Active ingredient

Sargramostim

Sargramostim is a recombinant human GM-CSF. The binding to GM-CSF receptors expressed on the surface of target cells (haematopoietic progenitors and mature immune cells), initiates an intracellular signalling cascade which induces the cellular responses (i.e., division, maturation, activation). GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, it can promote the proliferation and maturation of megakaryocytic and erythroid progenitors.

Read more about Sargramostim

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.